Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.53 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 4/20 | 0.42 |
| ▸ | HTR2A | P28223 | 4/20 | 0.42 |
| ▸ | DRD3 | P35462 | 4/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | MASP2 | O00187 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5849585 | 1.00 | MTNR1A (0.53) | MTNR1ASMYD3MAPTGAAKDM4E | |
| SCHEMBL30358033 | 1.00 | MTNR1A (0.53) | MTNR1ASMYD3MAPTGAAKDM4E | |
| Hydrochloric Acid SCHEMBL6531864 | 0.99 | MTNR1A (0.52) | MTNR1ASMYD3MAPTGAAKDM4E | |
| Hydrochloric Acid SCHEMBL5849580 | 0.99 | MTNR1A (0.52) | MTNR1ASMYD3MAPTGAAKDM4E | |
| Hydrochloric Acid SCHEMBL5849581 | 0.99 | MTNR1A (0.52) | MTNR1ASMYD3MAPTGAAKDM4E | |
| SCHEMBL30357968 | 0.89 | MTNR1A (0.51) | MTNR1ASMYD3MAPTGAAALDH1A1 | |
| SCHEMBL30358016 | 0.87 | MTNR1A (0.49) | MTNR1ASMYD3MAPTGAAKDM4E | |
| SCHEMBL10334541 | 0.85 | GAA (0.59) | MTNR1AMAPTGAAKDM4EBRD4 | |
| SCHEMBL3182006 | 0.85 | GAA (0.59) | MTNR1AMAPTGAAKDM4EBRD4 | |
| SCHEMBL30213277 | 0.85 | GAA (0.59) | MTNR1AMAPTGAAKDM4EBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-8541573-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541573-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541573-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| EP-2066659-B1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2013-08-28 | — | — | EP | disclosed |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBVIE, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBVIE, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8435978-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| EP-0894796-A1 | Imidazolines substituted with a heterocyclic ring as alpha-2 antagonists | ADIR ET COMPAGNIE (FR) | 1999-02-03 | — | — | EP | disclosed |
| EP-0815103-A1 | TRYPSIN AND THROMBIN INHIBITORS | Novartis AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996029327-A1 | TRYPSIN AND THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1996-09-26 | — | — | WO | disclosed |
| EP-0500686-B1 | TRICYCLIC [6,5,5]/[6,6,5]-FUSED OXAZOLIDINONE ANTIBACTERIAL AGENTS | UPJOHN CO (US) | 1996-01-24 | — | — | EP | disclosed |
| US-5324725-A | Antiinflammatory agent, antiallergen | KALI-CHEMIE PHARMA GMBH (DE) | 1994-06-28 | — | — | US | disclosed |
| US-5247090-A | Tricyclic [6,6,5]-fused oxazolidinone antibacterial agents | THE UPJOHN COMPANY (US) | 1993-09-21 | — | — | US | disclosed |
| US-5231188-A | Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents | THE UPJOHN COMPANY (US) | 1993-07-27 | — | — | US | disclosed |
| EP-0500686-A1 | TRICYCLIC 6,5,5]/ 6,6,5]-FUSED OXAZOLIDINONE ANTIBACTERIAL AGENTS. | UPJOHN CO (US) | 1992-09-02 | — | — | EP | disclosed |
| WO-1991007409-A1 | TRICYCLIC [6,5,5]/[6,6,5]-FUSED OXAZOLIDINONE ANTIBACTERIAL AGENTS | THE UPJOHN COMPANY (US) | 1991-05-30 | — | — | WO | disclosed |
| US-5017584-A | Antidepressant 2-(4,5-dihydro-1H-imidazolyl)-dihydro-1H-indoles, -1,2,3,4-tetrahydroquinolines and -1H-indoles, and methods of use thereas | STERLING DRUG INC. (US) | 1991-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | MTNR1A 48/4885SMYD3 4398/4885MAPT 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.